199 related articles for article (PubMed ID: 12949442)
1. Emerging non-statin LDL-lowering therapies for dyslipidemia and atherosclerosis.
Shah PK
Rev Cardiovasc Med; 2003; 4(3):136-41. PubMed ID: 12949442
[TBL] [Abstract][Full Text] [Related]
2. Effect of rosuvastatin compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for low-density lipoprotein cholesterol in a usual care setting.
Bullano MF; Wertz DA; Yang GW; Kamat S; Borok GM; Gandhi S; McDonough KL; Willey VJ
Pharmacotherapy; 2006 Apr; 26(4):469-78. PubMed ID: 16553504
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks.
McKenney JM
Am J Cardiol; 2005 Aug; 96(4A):60E-66E. PubMed ID: 16098846
[TBL] [Abstract][Full Text] [Related]
4. Clinically relevant pleiotropic effects of statins: drug properties or effects of profound cholesterol reduction?
Comparato C; Altana C; Bellosta S; Baetta R; Paoletti R; Corsini A
Nutr Metab Cardiovasc Dis; 2001 Oct; 11(5):328-43. PubMed ID: 11887430
[TBL] [Abstract][Full Text] [Related]
5. Models for describing relations among the various statin drugs, low-density lipoprotein cholesterol lowering, pleiotropic effects, and cardiovascular risk.
Robinson JG
Am J Cardiol; 2008 Apr; 101(7):1009-15. PubMed ID: 18359323
[TBL] [Abstract][Full Text] [Related]
6. The role of statins in reversing atherosclerosis: what the latest regression studies show.
Grines CL
J Interv Cardiol; 2006 Feb; 19(1):3-9. PubMed ID: 16483333
[TBL] [Abstract][Full Text] [Related]
7. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
Mora S; Ridker PM
Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
[TBL] [Abstract][Full Text] [Related]
8. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
Abdel-Maksoud M; Sazonov V; Gutkin SW; Hokanson JE
J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276
[TBL] [Abstract][Full Text] [Related]
9. Statins as the cornerstone of drug therapy for dyslipidemia: monotherapy and combination therapy options.
Jones PH
Am Heart J; 2004 Jul; 148(1 Suppl):S9-13. PubMed ID: 15211327
[TBL] [Abstract][Full Text] [Related]
10. Optimal medical management of peripheral arterial disease.
Rice TW; Lumsden AB
Vasc Endovascular Surg; 2006; 40(4):312-27. PubMed ID: 16959725
[TBL] [Abstract][Full Text] [Related]
11. Beyond LDL cholesterol: the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy.
Alagona P
Am J Manag Care; 2009 Mar; 15(3 Suppl):S65-73. PubMed ID: 19355805
[TBL] [Abstract][Full Text] [Related]
12. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
[TBL] [Abstract][Full Text] [Related]
13. Pleiotropic effects of HMG-CoA reductase inhibitors.
Bocan TM
Curr Opin Investig Drugs; 2002 Sep; 3(9):1312-7. PubMed ID: 12498006
[TBL] [Abstract][Full Text] [Related]
14. Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering.
Jones PH
Am J Cardiol; 2008 Dec; 102(12A):41L-47L. PubMed ID: 19084089
[TBL] [Abstract][Full Text] [Related]
15. Statins and diabetes.
Carmena R; Betteridge DJ
Semin Vasc Med; 2004 Nov; 4(4):321-32. PubMed ID: 15861314
[TBL] [Abstract][Full Text] [Related]
16. Pharmacologic treatment of type 2 diabetic dyslipidemia.
Moon YS; Kashyap ML
Pharmacotherapy; 2004 Dec; 24(12):1692-713. PubMed ID: 15585439
[TBL] [Abstract][Full Text] [Related]
17. Altering the pathophysiology of atherosclerosis: the multidimensional role of statins.
Clearfield MB
J Am Osteopath Assoc; 2010 Apr; 110(4 Suppl 4):S2-6. PubMed ID: 20453192
[TBL] [Abstract][Full Text] [Related]
18. Achieving greater reductions in cardiovascular risk: lessons from statin therapy on risk measures and risk reduction.
Ballantyne CM
Am Heart J; 2004 Jul; 148(1 Suppl):S3-8. PubMed ID: 15211326
[TBL] [Abstract][Full Text] [Related]
19. Benefits of lipid-lowering therapy in patients with type 2 diabetes mellitus.
Betteridge J
Am J Med; 2005 Dec; 118 Suppl 12A():10-5. PubMed ID: 16356802
[TBL] [Abstract][Full Text] [Related]
20. The treatment of dyslipidemia--what's left in the pipeline?
Rau O; Zettl H; Popescu L; Steinhilber D; Schubert-Zsilavecz M
ChemMedChem; 2008 Feb; 3(2):206-21. PubMed ID: 17963209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]